PhRMA defends FDA's OTC office as "important focal point" for OTC policy issues.
This article was originally published in The Tan Sheet
Executive Summary
PhRMA CALLS OFFICE OF OTC DRUGS "IMPORTANT FOCAL POINT" FOR POLICY ISSUES involving nonprescription drugs in a section- by-section analysis of its draft FDA reform legislation that is being circulated on Capitol Hill. The Pharmaceutical Research & Manufacturers Association noted that, since its inception in the early 1990s, the Office of OTC Drug Evaluation "has gradually become an important focal point for policy issues" related to over-the-counter drugs, and "has played a constructive role in the consideration of each proposed switch of a drug from prescription to nonprescription status."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning